Different molecular tests pointing to abnormal molecular mechanisms of thyroid cancer, such as genetic testing (BRAF, N-H-KRAS point mutations, and RET/PTC1, RET/PTC3, PAX8/PPAR rearrangements) or gene-expression classifiers (Veracyte, San Francisco, CA, USA, Thyroseq, Rye Brook, NY, USA), have been proposed to improve the preoperative risk assessment of malignancy on thyroid FNAs [5], but their performances are variable based on the markers tested (rule-in vs. rule-out tests) and their costs still limit the implementation in the routine clinical practice. Here, RET is linked to thyroid gland carcinoma.